Core Viewpoint - Yahui Pharmaceutical, established in March 2010 and listed on the Shanghai Stock Exchange in January 2022, focuses on innovative drug development for urogenital tumors and other diseases, showcasing strong technical capabilities in R&D [1] Financial Performance - For Q3 2025, Yahui Pharmaceutical reported revenue of 216 million yuan, ranking 97th out of 110 in the industry, significantly lower than the top competitors, East China Pharmaceutical (32.664 billion yuan) and Fosun Pharmaceutical (29.393 billion yuan), and below the industry average of 280 million yuan and median of 83.8 million yuan [2] - The company incurred a net loss of 261 million yuan, ranking 106th out of 110, with a stark contrast to the leading companies, Heng Rui Medicine (5.76 billion yuan) and Fosun Pharmaceutical (3.056 billion yuan), and below the industry average of 299 million yuan and median of 78.29 million yuan [2] Financial Ratios - As of Q3 2025, Yahui Pharmaceutical's debt-to-asset ratio was 19.20%, an increase from 10.12% year-on-year, but still below the industry average of 35.26%, indicating relatively low debt pressure [3] - The gross profit margin for the same period was 74.76%, down from 79.44% year-on-year, yet higher than the industry average of 57.17%, suggesting a competitive edge in profitability [3] Executive Compensation - The chairman and general manager, Pan Ke, received a salary of 3.5808 million yuan in 2024, an increase of 168,400 yuan from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 1.06% to 25,200, while the average number of circulating A-shares held per shareholder increased by 16.41% to 17,300 [5] - The top ten circulating shareholders included Penghua Pharmaceutical Technology Stock A, which held 6.1424 million shares, a decrease of 401,700 shares from the previous period [5] Growth Prospects - According to Pacific Securities, Yahui Pharmaceutical's revenue grew by 62% year-on-year in the first half of 2025, primarily driven by the commercial success of its products, Pazopanib tablets and Naltrindole tablets [5] - The company has a strong cash reserve of approximately 1.825 billion yuan as of the end of Q2 2025, and its core product APL-1702 is progressing well towards approval, expected by the end of 2025 or early 2026 [5] - Southwest Securities noted that the company is focusing on deepening its product pipeline with self-developed small molecules and ADC innovative drugs, projecting revenues of 300 million, 500 million, and 740 million yuan for 2025, 2026, and 2027 respectively [6]

Core Viewpoint - The company, Jiangsu Yahon Pharmaceutical Technology Co., Ltd., has released its quarterly report, ensuring the accuracy and completeness of the financial information presented, and confirming that there are no false records or misleading statements [2][3]. Financial Data Summary - The financial statements for the third quarter are unaudited, covering the period from the beginning to the end of the quarter [3][8]. - The report includes major accounting data and financial indicators, with all figures presented in Renminbi [3][8]. - The company has a share repurchase account holding 8,667,675 shares, representing 1.52% of total shares [5]. Non-Recurring Gains and Losses - The report indicates that non-recurring gains and losses are applicable, but specific details on significant items are not provided [4]. Shareholder Information - The report does not include information on major shareholders or changes in shareholding due to securities lending [6][7].

证券日报网讯10月29日晚间，亚虹医药发布公告称，公司于2025年10月29日召开职工代表大会并做出决 议，选举陈宝华先生为公司第二届董事会职工董事。 ...

格隆汇10月29日丨亚虹医药(688176.SH)发布三季报，2025年前三季度实现营业总收入2.16亿元，同比增 长55.74%；归属母公司股东净利润-2.49亿元，较上年同期亏损减少2189.32万元；基本每股收益为-0.44 元。 ...

中信证券股份有限公司 关于江苏亚虹医药科技股份有限公司 使用自有资金支付募投项目所需资金并以募集资金等额置换的 核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为江苏亚 虹医药科技股份有限公司（以下简称"公司"或"上市公司"）首次公开发行股 票并在科创板上市的保荐人，根据《证券发行上市保荐业务管理办法》、《上海 证券交易所科创板股票上市规则》等相关规定，对公司使用自有资金支付募投项 目所需资金并以募集资金等额置换事项进行了审慎核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意江苏亚虹医药科技股份有限公司首次 公开发行股票注册的批复》（证监许可〔2021〕3797 号）同意注册，公司向社 会公开发行人民币普通股 11,000 万股，每股面值人民币 1 元，每股发行价为人 民币 22.98 元，募集资金总额为人民币 252,780.00 万元，实际募集资金净额为人 民币 238,059.22 万元。以上募集资金到位情况已经立信会计师事务所（特殊普通 合伙）审验并出具了《验资报告》（信会计师报字[2021]第 ZA15998 号）。 二、募投项目的基本情况 根据《江苏 ...

证券代码：688176 证券简称：亚虹医药 公告编号：2025-040 江苏亚虹医药科技股份有限公司 关于选举第二届董事会职工董事及聘任高级管理人 员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏亚虹医药科技股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日召开职工代表大会并做出决议，选举陈宝华先生为公司第二届董事会职工董事； 于同日召开第二届董事会第十九次会议，审议通过了《关于聘任高级管理人员的 议案》，同意聘任陈宝华先生为公司财务负责人、董事会秘书。现将相关情况公 告如下： 一、 职工董事的选举情况 依据《中华人民共和国公司法》（以下简称"《公司法》"）、《上海证券交易所 科创板股票上市规则》和《江苏亚虹医药科技股份有限公司章程》（以下简称"《公 司章程》"）等法律法规、规范性文件的要求，公司于 2025 年 10 月 29 日召开职 工代表大会并做出决议，选举陈宝华先生（简历详见附件）为公司第二届董事会 职工董事，任期自公司职工代表大会决议之日起至第二届董事会任期届满之日止。 经公司董 ...

证券代码：688176 证券简称：亚虹医药 公告编号：2025-041 江苏亚虹医药科技股份有限公司 关于使用自有资金支付募投项目所需资金并以募集 资金等额置换的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏亚虹医药科技股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日召开第二届董事会第十九次会议，审议通过《关于使用自有资金支付募投项目 所需资金并以募集资金等额置换的议案》，同意公司（含实施募集资金投资项目 的子公司，下同）在募集资金投资项目（以下简称"募投项目"）实施期间，根 据实际情况使用自有资金支付募投项目所需资金，并以募集资金等额置换，从募 集资金专户划转等额资金至公司自有资金账户，该部分等额置换资金视同募投项 目使用资金。中信证券股份有限公司（以下简称"保荐人"）对本事项出具了明 确的核查意见。上述事项在董事会审批权限范围内，无需提交股东会审批。现将 相关情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意江苏亚虹医药科技股份有限公司首次 公开发行股票注册的批复》 ...

Financial Performance - The company's operating revenue for the third quarter reached ¥86,170,827.01, representing a year-on-year increase of 47.41%[5] - The total profit for the period was a loss of ¥91,109,604.17, with a net profit attributable to shareholders of ¥-86,732,800.64[5] - Total revenue for the first three quarters of 2025 reached ¥216,408,302.14, a significant increase of 55.7% compared to ¥138,951,629.03 in the same period of 2024[21] - Net loss for the first three quarters of 2025 was ¥261,050,841.03, slightly improved from a net loss of ¥271,342,070.94 in the same period of 2024[22] - Basic earnings per share for the first three quarters of 2025 were -¥0.44, compared to -¥0.48 in the previous year[23] Research and Development - Research and development (R&D) expenses amounted to ¥53,359,320.94, which is a decrease of 17.96% compared to the previous year[6] - R&D expenses accounted for 61.92% of operating revenue in the current period, down by 49.34 percentage points year-on-year[6] - Research and development expenses were ¥169,848,302.99, a decrease of 22.4% from ¥219,040,308.86 in the previous year[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,148,699,982.48, a decrease of 3.34% from the previous year[6] - The net assets attributable to shareholders decreased by 11.42% to ¥1,744,502,159.34 compared to the end of the previous year[6] - Total assets decreased to ¥2,148,699,982.48 from ¥2,222,991,903.79, reflecting a decline of 3.3%[19] - Total liabilities increased to ¥412,493,308.25, up from ¥252,618,105.29, marking a rise of 63.4%[19] - The company's equity attributable to shareholders decreased to ¥1,744,502,159.34 from ¥1,969,405,336.09, a decline of 11.4%[19] Cash Flow - The company reported a net cash flow from operating activities of ¥-301,798,901.12 for the year-to-date period[5] - Cash inflow from operating activities for the first three quarters of 2025 reached approximately $216.36 million, a significant increase from $128.58 million in the same period of 2024, representing a growth of about 68.2%[25] - The net cash flow from operating activities was negative at approximately -$301.80 million for 2025, compared to -$325.16 million in 2024, showing an improvement of about 7.1%[26] - The total cash outflow from operating activities was approximately $518.16 million in 2025, compared to $453.74 million in 2024, marking an increase of about 14.2%[26] Investments - Cash inflow from investment activities totaled approximately $4.56 billion in 2025, compared to $3.40 billion in 2024, indicating an increase of about 34.1%[26] - The net cash flow from investment activities was negative at approximately -$60.29 million in 2025, contrasting with a positive $443.76 million in 2024, reflecting a significant decline[26] - The company received approximately $8.07 million from investment in subsidiaries in 2025, while no such income was recorded in 2024[26] - The company reported a cash inflow from the recovery of investments of approximately $4.56 billion in 2025, compared to $3.40 billion in 2024, indicating a strong performance in investment recovery[26] Shareholder Information - The company has a total of 8,667,675 shares in its repurchase account, accounting for 1.52% of total shares[14] - The top shareholder, Pan-Scientific Holdings Co., Ltd., holds 31,858,481 shares, representing a significant portion of the company's equity[14] - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[15] Financial Statements - The financial statements for the quarter are unaudited, indicating that the figures are subject to final review and adjustments[17]

融券方面，亚虹医药10月27日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年80%分位水平，处于高位。 资料显示，江苏亚虹医药科技股份有限公司位于上海市浦东新区东育路221弄前滩世贸中心(三期)B栋 19F，成立日期2010年3月16日，上市日期2022年1月7日，公司主营业务涉及创新药物的研发、生产和 销售。主营业务收入构成为：抗肿瘤类产品96.34%，其他3.66%。 截至6月30日，亚虹医药股东户数2.55万，较上期增加2.09%；人均流通股14857股，较上期减少2.05%。 2025年1月-6月，亚虹医药实现营业收入1.30亿元，同比增长61.80%；归母净利润-1.62亿元，同比增长 11.84%。 10月27日，亚虹医药涨1.43%，成交额4611.83万元。两融数据显示，当日亚虹医药获融资买入额342.72 万元，融资偿还460.71万元，融资净买入-117.99万元。截至10月27日，亚虹医药融资融券余额合计1.94 亿元。 融资方面，亚虹医药当日融资买入342.72万元。当前融资余额1.94亿元，占流通市值 ...

亚虹医药于2022年1月7日在上交所科创板上市，发行数量为1.1亿股，发行价格为22.98元/股，保荐机构 为中信证券股份有限公司，保荐代表人为杨沁、程杰。 中国经济网北京10月15日讯亚虹医药(688176.SH)2025年半年度报告显示，2025年上半年，公司实现营 业收入1.3亿元，同比增长61.80%；归属于上市公司股东的净利润-1.62亿元，上年同期为-1.84亿元；归 属于上市公司股东的扣除非经常性损益的净利润-1.77亿元，上年同期为-1.97亿元；经营活动产生的现 金流量净额为-1.94亿元，上年同期为-2.43亿元。 | 人民币 | | --- | | 币种: | | 元 | | 单位: | | 主要会计数据 | 本报告期 (1-6月) | 上年同期 | 本报告期比上年 同期增减(%) | | --- | --- | --- | --- | | 营业收入 | 130,237,475.13 | 80,493,424.46 | 61.80 | | 利润总额 | -170,534,193.48 | -184,702,091.44 | 不适用 | | 归属于上市公司股东的净利润 | -162,214 ...